CN1961071A - 使用可选剪接在真核细胞中表达多肽多聚体的方法和构建物 - Google Patents

使用可选剪接在真核细胞中表达多肽多聚体的方法和构建物 Download PDF

Info

Publication number
CN1961071A
CN1961071A CNA2005800156216A CN200580015621A CN1961071A CN 1961071 A CN1961071 A CN 1961071A CN A2005800156216 A CNA2005800156216 A CN A2005800156216A CN 200580015621 A CN200580015621 A CN 200580015621A CN 1961071 A CN1961071 A CN 1961071A
Authority
CN
China
Prior art keywords
cell
carrier
polypeptide
antibody
splicing site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800156216A
Other languages
English (en)
Chinese (zh)
Inventor
霍利·普伦蒂斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec MA Inc filed Critical Biogen Idec MA Inc
Publication of CN1961071A publication Critical patent/CN1961071A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
CNA2005800156216A 2004-03-15 2005-03-15 使用可选剪接在真核细胞中表达多肽多聚体的方法和构建物 Pending CN1961071A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55347804P 2004-03-15 2004-03-15
US60/553,478 2004-03-15

Publications (1)

Publication Number Publication Date
CN1961071A true CN1961071A (zh) 2007-05-09

Family

ID=34994241

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800156216A Pending CN1961071A (zh) 2004-03-15 2005-03-15 使用可选剪接在真核细胞中表达多肽多聚体的方法和构建物

Country Status (10)

Country Link
US (2) US7569362B2 (enExample)
EP (1) EP1733034A4 (enExample)
JP (1) JP2007529223A (enExample)
KR (1) KR20070004026A (enExample)
CN (1) CN1961071A (enExample)
AU (1) AU2005222963B2 (enExample)
BR (1) BRPI0508862A (enExample)
CA (1) CA2559280A1 (enExample)
IL (1) IL178051A (enExample)
WO (1) WO2005089285A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105658665A (zh) * 2013-08-06 2016-06-08 格兰马克药品股份有限公司 表达构建体和用于表达真核细胞中的多肽的方法
CN107881196A (zh) * 2011-12-22 2018-04-06 弗·哈夫曼-拉罗切有限公司 表达载体组织、新的生产用细胞产生方法及其在重组产生多肽中的用途
CN113302202A (zh) * 2018-07-17 2021-08-24 脑若脉仁股份有限公司 利用表达胰岛素样生长因子1异构体的脱氧核糖核酸构建体的神经病变的治疗
CN114150021A (zh) * 2021-11-26 2022-03-08 武汉枢密脑科学技术有限公司 一种包含重叠开放阅读框的基因的表达盒及其在昆虫细胞中的应用

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2355459B (en) * 1999-11-29 2001-09-26 Isis Innovation A dominant conditional lethal genetic system
GB2402675B (en) * 2003-05-12 2008-02-20 Oxitec Ltd Resistance dilution
GB2403475B (en) * 2003-07-01 2008-02-06 Oxitec Ltd Stable integrands
GB2404382B (en) 2003-07-28 2008-01-30 Oxitec Ltd Pest control
CA2559280A1 (en) * 2004-03-15 2005-09-29 Biogen Idec Ma Inc. Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing
US20090183269A1 (en) * 2006-02-10 2009-07-16 Oxitec Limited Gene expression system using alternative splicing in insects
GB2443186A (en) 2006-10-25 2008-04-30 Oxitec Ltd Expression system for mediating alternative splicing
EA200802061A1 (ru) 2006-03-28 2009-04-28 Байоджен Айдек Эмэй Инк. Антитело или его фрагмент, специфично связывающееся с рецептором 1 инсулиноподобного фактора роста (igf-r1) (варианты), композиция на его основе, полинуклеотид, кодирующий вариабельную область антитела (варианты), содержащие полинуклеотид композиция (варианты) и вектор, содержащая вектор клетка-хозяин (варианты), способ продуцирования антитела или его фрагмента (варианты) и способ лечения гиперпролиферативного заболевания у животного организма
EP2018430A1 (en) * 2006-05-16 2009-01-28 Millegen Method for expressing polypeptides in eukaryotic cells using alternative splicing
KR101202498B1 (ko) * 2006-05-17 2012-11-16 에프. 호프만-라 로슈 아게 폴리펩티드 생성 세포
US20080045419A1 (en) * 2006-08-18 2008-02-21 University Of North Texas Health Science Center At Fort Worth Screening Assay
MX2010004007A (es) * 2007-10-15 2010-06-15 Chugai Pharmaceutical Co Ltd Metodo para la produccion de un anticuerpo.
WO2009059235A2 (en) * 2007-11-01 2009-05-07 Facet Biotech Corporation Immunoglobulin display vectors
KR100907221B1 (ko) * 2009-01-22 2009-07-10 한국과학기술원 새로운 조성의 황색 발광 Ｃｅ3+부활 칼슘 실리케이트 황색형광체를 포함하는 백색 발광 다이오드
WO2011125833A1 (ja) 2010-03-31 2011-10-13 学校法人 慶應義塾 生体分子相互作用解析ツールの構成とそれを用いた解析方法
US9220774B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Methods of treating cancer by administering anti-GPR49 antibodies
AU2012332588B2 (en) 2011-11-01 2017-09-07 Bionomics, Inc. Methods of blocking cancer stem cell growth
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
AU2012332587B2 (en) 2011-11-01 2017-02-23 Bionomics, Inc. Antibodies and methods of treating cancer
GB2500113A (en) 2012-03-05 2013-09-11 Oxitec Ltd Arthropod male germline gene expression system
GB201303932D0 (en) 2013-03-05 2013-04-17 Oxitec Ltd Muscle actin promoter
AU2014246731A1 (en) * 2013-03-30 2015-11-19 Usha Biotech Limited Methods and constructs for expressing biologically active proteins in mammalian cells
EP3126397B1 (en) 2014-04-04 2020-01-29 Bionomics, Inc. Humanized antibodies that bind lgr5
GB2526867A (en) 2014-06-05 2015-12-09 Oxitec Ltd Gene expression system
AU2017239038B2 (en) 2016-03-22 2024-06-27 Bionomics Inc Administration of an anti-LGR5 monoclonal antibody
WO2018029534A1 (en) 2016-08-12 2018-02-15 Oxitec Ltd. A self-limiting, sex-specific gene and methods of using
EP3472198B1 (en) 2016-09-29 2020-03-04 H. Hoffnabb-La Roche Ag Improved method for selecting polypeptide producing cells
AR117409A1 (es) 2018-03-29 2021-08-04 Oxitec Ltd Noctuidas autolimitantes
WO2021041924A2 (en) * 2019-08-30 2021-03-04 Baylor College Of Medicine System for regulating gene expression

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2759053A1 (de) * 1977-12-30 1979-07-12 Uhlin Verfahren zum herstellen von genprodukten von plasmid-dns
GB2048894A (en) * 1979-05-11 1980-12-17 Gist Brocades Nv Plasmid
JPS58192900A (ja) * 1982-05-04 1983-11-10 Ajinomoto Co Inc 複合プラスミド
US5043270A (en) * 1989-03-31 1991-08-27 The Board Of Trustees Of The Leland Stanford Junior University Intronic overexpression vectors
SG84484A1 (en) * 1991-02-25 2001-11-20 Ciba Geigy Ag Improved yeast vectors
US5587308A (en) * 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5561053A (en) * 1994-08-05 1996-10-01 Genentech, Inc. Method for selecting high-expressing host cells
CA2309344A1 (en) * 1997-11-12 1999-05-20 Valentis, Inc. Expression plasmids for multiepitope nucleic acid-based vaccines
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US6900010B2 (en) * 1999-01-25 2005-05-31 Musc Foundation For Research Development Compositions and methods for detecting human immunodeficiency virus
WO2000075342A1 (fr) * 1999-06-04 2000-12-14 Nippon Institute For Biological Science Nouveau vecteur plasmidique
JP2006512061A (ja) * 2002-11-14 2006-04-13 ジェネンテック・インコーポレーテッド イントロン融合コンストラクトおよび高発現産生細胞系を選択するための使用方法
MXPA05008523A (es) * 2003-02-14 2005-10-20 Biogen Idec Inc Un casete de expresion y vector para la expresion transitoria o estable de moleculas exogenas.
CA2559280A1 (en) * 2004-03-15 2005-09-29 Biogen Idec Ma Inc. Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107881196A (zh) * 2011-12-22 2018-04-06 弗·哈夫曼-拉罗切有限公司 表达载体组织、新的生产用细胞产生方法及其在重组产生多肽中的用途
CN105658665A (zh) * 2013-08-06 2016-06-08 格兰马克药品股份有限公司 表达构建体和用于表达真核细胞中的多肽的方法
CN113302202A (zh) * 2018-07-17 2021-08-24 脑若脉仁股份有限公司 利用表达胰岛素样生长因子1异构体的脱氧核糖核酸构建体的神经病变的治疗
CN113302202B (zh) * 2018-07-17 2024-01-30 赫利世弥斯株式会社 利用表达胰岛素样生长因子1异构体的脱氧核糖核酸构建体的神经病变的治疗
CN114150021A (zh) * 2021-11-26 2022-03-08 武汉枢密脑科学技术有限公司 一种包含重叠开放阅读框的基因的表达盒及其在昆虫细胞中的应用

Also Published As

Publication number Publication date
AU2005222963B2 (en) 2009-10-29
KR20070004026A (ko) 2007-01-05
WO2005089285A2 (en) 2005-09-29
US7569362B2 (en) 2009-08-04
AU2005222963A1 (en) 2005-09-29
IL178051A (en) 2010-12-30
US20100009410A1 (en) 2010-01-14
EP1733034A4 (en) 2010-01-20
CA2559280A1 (en) 2005-09-29
BRPI0508862A (pt) 2007-09-04
US20050221430A1 (en) 2005-10-06
WO2005089285A3 (en) 2006-01-19
IL178051A0 (en) 2006-12-31
EP1733034A2 (en) 2006-12-20
JP2007529223A (ja) 2007-10-25

Similar Documents

Publication Publication Date Title
CN1961071A (zh) 使用可选剪接在真核细胞中表达多肽多聚体的方法和构建物
CN1198648C (zh) 特异于呼吸道合胞病毒融合蛋白的高亲和性人单克隆抗体
CN1650011A (zh) Erbb3用于肿瘤治疗的方法和组合物
CN1606453A (zh) Cripto阻断抗体及其用途
CN1360638A (zh) 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
CN1203603A (zh) 由抗－Fc受体抗体组成的治疗化合物
CN1268645C (zh) 含有抗－fc受体结合剂的治疗化合物
CN1738646A (zh) 可用来抵御并治疗hiv感染的去免疫化单克隆抗体
CN1703427A (zh) 通过同时加载和激活抗原呈递细胞的选定的亚型产生并且控制t细胞的效应物谱的方法和组合物
CN1602316A (zh) 黄病毒ns1亚单位疫苗
CN1671423A (zh) 新型嵌合cd154
CN1561229A (zh) 病毒外壳蛋白/受体嵌合体及使用方法
CN1520423A (zh) 来源于IgE的Cε3或Cε4区的抗原决定基或拟表位,其拮抗物,及其治疗用途
CN1642980A (zh) 拮抗性抗hFAS配基人类抗体及其片段
CN1632124A (zh) 编码h5亚型禽流感病毒血凝素蛋白的基因及其应用
CN1703240A (zh) LFA－1α亚基抗体及使用方法
CN101076351A (zh) 用于治疗前列腺癌的细胞因子表达细胞疫苗
CN1768078A (zh) 针对丙型肝炎病毒e1e2复合体的抗体、hcv颗粒的组合物和药物组合物
CN1874787A (zh) 预防/治疗hbv感染和hbv介导疾病的组合物
CN1698881A (zh) 病毒感染的长效融合肽抑制剂
CN1884556A (zh) 一种具有多重特异性抗癌机制的溶瘤腺病毒突变体
CN1711018A (zh) 导入ganp基因的转基因哺乳动物及其应用
Zhang et al. Development of stable HEK293T cell pools expressing CSFV E2 protein: A potential antigen expression platform
CN101039955A (zh) 与sars冠状病毒刺突蛋白相关的核酸、多肽、表达方法和免疫原性组合物
CN1290864C (zh) 一种抗cd20嵌合抗体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20070509

C20 Patent right or utility model deemed to be abandoned or is abandoned